精彩内容日前,新华制药发布公告,公司的阿仑膦酸钠口服溶液以仿制3类报产获批,视同过评,是该产品第2家国产企业。米内网数据显示,阿仑膦酸在2024年中国三大终端六大市场销售额超过7亿元,是影响骨结构及其矿化的药物(化+生)通用名TOP4品种。来源:米内网一键检索阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松症,以预防髋部和脊柱骨折(椎骨压缩性骨折)和男性骨质疏松以增加骨量。近年中国三大终端六大市场...
Source Link精彩内容日前,新华制药发布公告,公司的阿仑膦酸钠口服溶液以仿制3类报产获批,视同过评,是该产品第2家国产企业。米内网数据显示,阿仑膦酸在2024年中国三大终端六大市场销售额超过7亿元,是影响骨结构及其矿化的药物(化+生)通用名TOP4品种。来源:米内网一键检索阿仑膦酸钠口服溶液适用于治疗绝经后妇女的骨质疏松症,以预防髋部和脊柱骨折(椎骨压缩性骨折)和男性骨质疏松以增加骨量。近年中国三大终端六大市场...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.